Rheonix Raises $6M, Bringing Total Series A Round to $18.6M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rheonix has closed on a $6 million extension to its Series A financing round, bringing the total raised in the round to $18.6 million.

Tony Eisenhut, the firm's president, told GenomeWeb Daily News today that the funds will be used to continue developing four tests: a warfarin-sensitivity test; a sexually transmitted disease panel; an HIV panel; and a CYP2C19 test for predicting response to the anti-platelet drug Plavix (clopidogrel).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.